Ophthalmology

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats

Automated assistance controls tremor, reduces fatigue, and helps avoid inadvertent injury

Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD

Evidence-based medicine can lead to personalized care, better results for patients

Ophthalmologists remain in touch with colleagues while maintaining social distancing

This ability would unlock possibilities for repairing tissue damaged by disease

Watchful waiting may prove to be beneficial in complicated cases

Intravitreal gene therapy continues to be well tolerated; shows robust efficacy

Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.

Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.

Study explores correlations between functional and structural tests

Susan Coultas, PhD, and Preeya Gupta, MD, share their hopes for continued innovation in the ophthalmic space — including dry eye and retina — as well as the importance of the clinical research process.

The application of sub-silicone oil TA crystals over relaxing retinectomy sites is a viable option in patients with complex RD with extreme PVR.

Find out how the LIGHTSITE I results may pave the way for a new treatment approach.

The FDA has issued an emergency use authorization to allow treatment with COVID-19 convalescent plasma for patients who are hospitalized with the disease.

Ophthalmologists share what keeps them up at night in the ophthalmic profession amid the pandemic.

In this second installment, ophthalmologists share how their expectations for "the year of the eye" have compared and contrasted to reality amid the global pandemic.

Ophthalmologists share their outlook for the current state and future of the ophthalmic profession, how coronavirus pandemic has altered the profession as well as how —now, more than ever — patient care remains a number one priority for ophthalmologists.

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates, and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

Subretinal transplantation of human embryonic stem cells (hESC)-derived retinal pigment epithelial (RPE) cells in patients with AMD and geographic atrophy (GA) appears well tolerated, according to date presented during ARVO 2020.

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

The FDA has granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.

Patents gained less vision in clinical practice than patients on clinical trials

A team of Turkish investigators detected COVID-19 viral material on the environmental surfaces of an ophthalmology examination room despite triage systems to exclude patients with the virus.

This action will result in 2 separate companies

Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?